Rising Biosciences Inc (RBII)

[maronti1]

RISING BIOSCIENCES, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 & 2019
(UNAUDITED)
Three Months Ended September, 30 Nine Months Ended September, 30

2020

2019 2020 2019
REVENUES:
Sales $ 389,660 $ 28,104 $ 751,295 $ 134,534
TOTAL REVENUE 389,660 28,104 751,295 134,534
COST OF SALES 78,322 47,166 187,845 171,381
GROSS MARGIN 311,338 (19,062) 563,450 (36,847)
OPERATING EXPENSES:
Administrative expenses 82,231 17,662 109,120 57,255
Salaries 34,400 1,650 45,200 9,150
Professional Fees 8,975 22,325 12,771 40,049
Depreciation 8,380 8,380 25,140 25,140
Transfer Agent Fees 450 150 750 900
Total Operating expenses 134,436 50,167 192,981 132,159
NET OPERATING INCOME/
(LOSS)
176,902 (69,229) 370,469 (169,006)
OTHER INCOME/(EXPENSES)
Finance and interest fees (22,264) (19,908) (69,405) (53,503)
Total Other Income/(Expenses) (22,264) (19,908) (69,405) (53,503)
NET INCOME/ (LOSS) $ 154,638 $ (89,137) $ 301,064 $ (222,509)
Basic and Diluted Loss per Common
Share
$ .000146 $ (.00011) $ .000284 $ (0.0006)
Weighted Average Number of
Common Shares Outstanding
1,059,725,348 843,725,348 1,059,725,348 843,725,348
The accompanying notes are an integral part of the financial statements.
F-3